In vivo neuroblastoma (NB) xenograft model, resistant to the DNA-topoisomerase I inhibitor irinotecan (CPT-11), has been established to study resistance mechanisms acquired in a therapeutic setting. Common mechanisms of resistance were not involved in this resistance. Thus, we compared the gene expression profiles of sensitive, resistant, and reverted tumors using cDNA expression arrays. Expression of selected transcripts was confirmed by quantitative real-time PCR. We found that pleiotrophin (PTN), a heparin-binding growth factor, was the only gene significantly affected: PTN gene expression was downregulated in all resistant tumors (8-14-fold) as compared to sensitive tumors, and was increased (2-4-fold) in all reverted tumors as compared to resistant tumors. PTN thus appeared to be a likely candidate gene associated with resistance to CPT-11 in this in vivo model. To investigate the direct implication of PTN in NB, we transfected two NB cell lines with RNA interferences in order to silence PTN. PTN failed to demonstrate implication in resistance to CPT-11 in vitro but could influence sensitivity to CPT-11 exclusively through an in vivo mechanism. Indeed, vasculature was significantly enhanced in resistant NB xenografts compared to sensitive and reverted xenografts, and we suggest that PTN is acting in our resistant in vivo NB model as an angiostatic factor.
Introduction
Neuroblastoma (NB) is one of the most common solid tumors in childhood and is responsible for approximately 7.5% of all cancers affecting children younger than 15 years of age (Ries et al., 1999) . It is a neural crest-derived embryonal cancer of the sympathetic nervous system. Biological parameters such as MYCN gene amplification (Brodeur et al., 1984) , loss of heterozygosity of chromosome 1p (Fong et al., 1989; Hayashi et al., 1989) diploidy (Look et al., 1991) , and MDR1 gene overexpression (Bourhis et al., 1989) have been identified as strong predictors of a poor outcome.
CPT-11 a semisynthetic water-soluble analog of camptothecin, is a DNA-topoisomerase I inhibitor and has demonstrated antitumor activity against a wide spectrum of both adult and pediatric xenografts in preclinical studies (Komuro et al., 1994; Vassal et al., 1996; Thompson et al., 1997a) . We have previously shown that intravenous (i.v) treatment with CPT-11 resulted in extensive tumor regression and growth delay in three different NB xenograft models (Vassal et al., 1996) . Thompson et al. (1997b) demonstrated activity of oral CPT-11 against a panel of six NB xenografts. Similar effects have been reported for topotecan, the topoisomerase I inhibitor, which induced tumor regression and a significant tumor growth delay in animals bearing NB xenografts (Vassal et al., 1997) . Initial phase I trials of CPT-11 in children evaluated several doses and schedules and some partial responses or disease stabilization were reported in patients with NB (Furman et al., 1999; Blaney et al., 2001; Vassal et al., 2003) . However, in a European phase II study in children with relapsed or refractory NB, CPT-11 showed no clinically useful activity (Vassal et al., 2002) , suggesting the presence of drug resistance mechanisms.
The emergence of drug resistance in cancer is a major hurdle to successful chemotherapy, especially in NB where treatment failures in high-risk NB is largely attributable to resistance to a wide spectrum of cytotoxic drugs. Drug resistance has been described in a number of cell lines selected for their resistance to topoisomerase I inhibitors Rubin et al., 1996) . To date, resistance to CPT-11 has been studied mainly in vitro, a situation in which most parameters are controlled. However, this controlled situation cannot be equated with that likely to occur in a therapeutic setting. We therefore established an in vivo NB xenograft model resistant to CPT-11, in order to study the mechanisms involved in acquired resistance in a therapeutic setting.
Prolonged exposure of a NB xenograft to CPT-11 allowed resistance to be acquired progressively (Calvet et al., 2004) . This resistant xenograft (IGR-NB8-R) was devoid of topoisomerase I alteration and of overexpresssion of three members of the ATP-binding cassette (ABC) transporter family that confer multidrug resistance (MDR). Furthermore, this resistance was reversible after 15 in vivo passages without treatment. This model did not seem to involve any of the mechanisms usually observed in vitro in preclinical studies and suggested a novel mechanism of resistance. Elucidating the resistance mechanism in IGR-NB8-R would allow us to take a step forward in our understanding of acquired chemoresistance and to better target the clinical development of CPT-11. To investigate alterations leading to this in vivo resistance, we analysed the expression pattern of 588 cancer-related genes using cDNA expression macroarray technology in CPT-11 sensitive, resistant and reverted NB xenograft tumors. We report that in vivo exposure to clinically relevant doses of CPT-11-induced pleiotrophin (PTN) downregulation, and we hypothesize that PTN could play a role as an inducer of chemosensitivity of NB to topoisomerase I inhibitors in vivo.
Results
Atlas human cancer cDNA expression profile: data collection and analysis RNA isolated from 3 CPT-11-sensitive, five resistant and three reverted xenograft tumors was used in hybridization experiments with cDNA expression arrays containing 588 cancer-related genes and nine housekeeping genes. The gene expression profile of each hybridization was compared to that of all the other hybridizations that is 55 comparisons. No signals were visible in the blank spot, that is a negative control indicating that hybridization with the Atlas human cancer cDNA expression array was highly specific (Figure 1) .
The 55 comparisons of the 11 hybridizations were analysed by AtlasImage software and showed that 159 of the 588 genes displayed a significant change in expression. These genes are involved in a wide variety of cellular mechanisms, including regulation of the cell cycle, proliferation and apoptosis (Table 1) . However, these changes in gene expression were not reproducible when all resistant, sensitive and reverted tumor samples were considered. In order to select candidate genes that presented a deregulation consistent with both acquired and reversible resistance phenotypes, we used a two-step process.
First, the three sensitive tumors were compared to the five resistant tumors (15 comparisons). Genes were selected if there was a significant change in expression with an intensity ratio X1.75, and if this deregulation was observed in at least six of the 15 comparisons. Only 18 genes fulfilled this criterion. Among them, for example, the caspase-10 gene displayed significant upregulation in resistant versus sensitive in eight of the 15 comparisons, whereas the PTN gene displayed a significant level of downregulation in resistant versus sensitive in 15 of the 15 comparisons.
We then compared the three reverted tumors to the five resistant tumors leading to a total of 15 comparisons. Genes were selected if there was a significant change in expression with an intensity ratio X1.75, if this deregulation was in the same direction (down-or upregulation) as comparisons in the first step and if it was observed in at least six of the 15 comparisons. Only the PTN gene fulfilled this criterion displaying a significant level of upregulation in reverted versus resistant in 13 of the 15 comparisons. The caspase-10 gene displayed a significant level of downregulation in only four of the 15 comparisons.
Finally, no significant difference in PTN gene expression was observed when sensitive tumors were compared to each reverted tumor (nine comparisons) and when each of the three tumor groups was compared between themselves (16 comparisons).
Thus, PTN was the only gene found to be significantly affected which is consistent with both acquired resistance and reverted phenotypes. PTN was downregulated in all resistant tumors as compared to all sensitive tumors and gene expression was once again upregulated in reverted tumors as compared to resistant tumors ( Figure 1 ). PTN is a heparin-binding growth factor with diverse functions including angiogenesis and proliferation. PTN appeared to be a likely candidate gene associated with the resistance of our in vivo NB model to CPT-11, and its potential role was further analysed.
PTN mRNA expression in CPT-11-resistant NB xenografts To validate array data, real-time RT-PCR was performed for PTN expression in three independent tumors of each passage (P1 sensitive tumors, P24 and P32 resistant tumors, P8P15 and P8P16 reverted tumors) (Figure 2) . Consistent with the cDNA Figure 1 Representative gene expression profile of a sensitive (IGR-NB8) tumor at passage 1 (a), a resistant (IGR-NB8-R) tumor at passage 19 (b), and a reverted (IGR-NB8-r) tumor at passage P8P16 (eight passages with treatment prolonged over 15 passages without any exposure to CPT-11) (c). Atlas human cDNA expression arrays (Clontech) include 588 cancer-related human cDNAs, nine housekeeping control cDNAs, and negative controls in duplicate immobilized on a nylon membrane. Boxes highlight the position and expression of PTN. These boxes are further magnified and displayed as insets below each array. macroarray result, PTN gene expression showed 8-14-fold lower expression in resistant tumors as compared to sensitive tumors. In addition, a 2-4-fold increase in PTN expression was observed in all reverted tumors as compared to the resistant tumors. These results confirmed the gene expression profile data and emphasized the potential role of PTN in in vivo acquired CPT-11 resistance.
PTN mRNA and protein expression in NB cell lines In order to evaluate the level of PTN expression in NB cell lines and knockdown or silence this expression using a small interfering RNA (siRNA) experiment, we next investigated six NB cell lines, CHP-212, NJB, SH-SY5Y, SK-N-AS, IGR-N91 and IGR-NB8 using realtime RT-PCR and Western blot. The IGR-NB8 cell line was derived from the IGR-NB8 xenograft at an early passage. Real-time RT-PCR ( Figure 3a) showed two groups of cell lines with distinct PTN expression. CHP-212, NJB, SH-SY5Y exhibited very low PTN expression whereas IGR-NB8, IGR-N91 and SK-N-AS showed 6-40-fold higher PTN expression. Western blot analysis confirmed these results showing high-PTN protein expression in IGR-NB8, IGR-N91 and SK-N-AS (Figure 3b) , and low expression in CHP-212, NJB and SH-SY5Y. Thus, two groups of NB cell lines could be identified according to high or low PTN expression.
Sensitivity of NB cell lines to SN-38 and topotecan
To determine if PTN expression is a crucial factor in sensitivity to topoisomerase I inhibitors, we performed an MTT assay on PTN low-expressive NJB, SH-SY5Y and CHP-212 and the high-expressive SK-N-AS, IGR-NB8 and IGR-N91 cell lines using SN-38 and topotecan. SN-38, the active metabolite of CPT-11, and topotecan inhibited viability of NB cells in a concentration-dependent manner (Figure 4) . After a 72-h exposure to the drugs in vitro, cell lines exhibited a wide IC 50 spectrum , ranging from 2.7 to >100 ng/ml for SN-38 and 16.1 to >1000 nM for topotecan (Table 2) . Interestingly, cell lines with high PTN expression ( Figure 4a and c) showed sensitivity to the two topoisomerase I inhibitors, with an IC 50 value of 2.8-8.7 ng/ml for SN-38 and 24.8-170 nM for topotecan Figure 2 Histogram of mRNA relative expression using real-time quantitative PCR (TaqMan). & Sensitive tumors at passage 1 (P1), ' resistant tumors at passage 24 and passage 32 (P24 and P32) and reverted tumor after eight passages with treatment followed by 15 or 16 passages without treatment (P8P15 and P8P16), respectively. Each value is the mean of three tumors at each passage.
PTN a candidate gene for in vivo sensitivity to CPT-11 L Calvet et al whereas two of the three cell lines with low PTN expression, namely NJB and CHP-212 cells ( Figure 4b and d) showed higher IC 50 values of 49 and >100 ng/ml for SN38 and >1000 nM for topotecan. However, the SH-SY5Y cell line with low PTN expression was highly sensitive (Figure 4b and d) with an IC 50 value of 2.7 ng/ ml for SN38 and 16.1 nM for topotecan (Table 2) . Multiple factors may determine chemosensitivity and could explain these different chemosensitivity profiles. We hypothesized that PTN is a marker of drug sensitivity to topoisomerase I inhibitors that may contribute to a sensitive phenotype
PTN inhibition in NB cells
We next evaluated whether PTN downregulation could confer resistance to topoisomerase I inhibitors. We used pRetroSUPER (pRS)-short interfering (si)RNA expression system to silence PTN expression in SK-N-AS and Figure 6 ). SN-38 did not significantly alter the viability of IGR-NB8 cells after pRS-PTN transfection (Figure 6a ). IC 50 values for IGR-NB8, the parental cell line and for transfected cell lines were approximately the same, about 8 ng/ml. In addition, SN-38 did not significantly alter the cell viability of SK-N-AS-transfected cells (Figure 6b ). Overall, these results indicate that PTN downregulation does not influence cell sensitivity to SN-38 in vitro.
Comparison of microvessel density and microvessel surface proportions in xenografts We then hypothesized that PTN might be involved in a sensitivity/resistant phenotype exclusively in vivo. PTN is a secreted polypeptide growth factor that plays a role in the regulation of angiogenesis processes in vivo. To establish whether intratumor angiogenesis was modulated in our model, we investigated microvessel density (MVD) using the endothelial cell marker CD34 in six sensitive, eight resistant and eight reverted NB xenografts. In order to quantify vasculature, we performed automatic microvessel detection. After scanning the histological section (Figure 7a ), a binary image of microvessels was obtained with PixCyt s software (Figure 7b ). MVD and microvessel surface proportion (MSP) were calculated and are presented in Table 3 .
CD34 expression was weak in sensitive xenografts (Figure 7c 1) compared to resistant and reverted xenografts (Figure 7c 2,3) as evidenced by the brown staining. A significant increase in MVD by approximately 40 and 55% was found in the resistant xenografts as compared to sensitive and reverted xenografts, respectively. Similarly, MSP also showed a 50% increase in resistant xenografts as compared to sensitive xenografts (P ¼ 0.0007) and a 70% increase in resistant xenografts as compared to reverted xenografts (P ¼ 0.0002) (Figure 8 ). We concluded that intratumor angiogenesis was increased in CPT-11-resistant IGR-NB8-R NB xenografts. It is well established that PTN is involved in the control of angiogenesis, although opposite activities in angiogenesis processes (both induction and inhibition) have been observed. We argued that angiogenesis contributes to in vivo resistance to CPT-11 in our NB model and that PTN could play an important role in this process in vivo.
Discussion
The understanding of molecular resistance mechanisms and the use of new classes of therapeutic agents are essential to improve clinical outcome of poor prognosis NB. To date, mechanisms that confer clinical resistance to topoisomerase I inhibitors, such as irinotecan, have not been fully characterized in the clinical setting. Our in vivo NB model resistant to irinotecan is of great interest, because resistance mechanisms usually described in vitro, such as, topoisomerase I alteration and multidrug-resistance-related protein overexpression, were not observed (Calvet et al., 2004) .
We used macroarray technology to identify candidate genes that would allow us to elucidate the resistance mechanism involved in this model. Atlas cDNA expression arrays, designed to include genes reported to play key roles in oncogenesis, explored successfully gene expression profiles of sensitive, resistant, and reverted NB xenografts, and detected PTN being the only gene significantly affected consistent with both acquired resistance and reverted phenotype. PTN was downregulated in all resistant tumors as compared to sensitive tumors, and increased in all reverted tumors as compared to resistant tumors. PTN a candidate gene for in vivo sensitivity to CPT-11 L Calvet et al PTN (Li et al., 1990) , also called heparin-binding growth-associated molecule (HB-GAM) (Rauvala, 1989) or heparin affin regulatory peptide (HARP) (Courty et al., 1991 ) is a heparin-binding growth factor with diverse biological roles (Deuel et al., 2002; Kadomatsu and Muramatsu, 2004) . PTN exhibits a wide range of cancer-related activity such as the ability to promote cell growth (Milner et al., 1989) , angiogenic activity (Laaroubi et al., 1994; Choudhuri et al., 1997) , as well as antiapoptotic activity (Bowden et al., 2002) , and transforming activity (Chauhan et al., 1993) . PTN has also been reported to act as a differentiation factor (Rauvala, 1989; Deuel et al., 2002) and is able to induce the proliferation of various cell types including fibroblasts, epithelial cells and endothelial cells (Courty et al., 1991; Fang et al., 1992) . The diversity of PTN signaling responses makes this protein a promising molecular target for the treatment of cancer.
Several lines of evidence suggest that PTN plays a role in tumor survival. However, PTN was surprisingly downregulated in IGR-NB8-R-resistant tumors. This is not the first time that the function of PTN is debated. PTN expression in NIH 3T3 cells was found to be associated with quiescence, and suppression of PTN was found to be related to oncogenic transformation (Corbley, 1997) . Furthermore, Nakagawara et al. (1995) reported that PTN expression is correlated with a better prognosis in NB. PTN was highly expressed in favorable NB (stages I, II, IVs) but extremely low in unfavorable stages (stages III and IV), suggesting that PTN may play an important role in the clinical behavior of these tumors and that PTN could be a marker for a less tumorigenic phenotype.
To better understand the role of PTN in CPT-11 resistance, six NB cell lines were tested for their sensitivity to SN-38 and topotecan, two topoisomerase I inhibitors. We demonstrated that PTN does not have a determinant role in sensitivity to topoisomerase I inhibitors in vitro. However, tumor cells receive survival signals from the extracellular microenvironment in vivo PTN a candidate gene for in vivo sensitivity to CPT-11 L Calvet et al and the lack of microenvironmental factors might cause discordance between sensitivity to chemotherapy in vitro and in vivo. This discordance has been reported by some investigators. In an EMT-6 mouse breast tumor model resistant to alkylating agents, Teicher et al. (1990) reported that, in spite of high levels of resistance in vivo, no significant resistance was observed when these tumor cells were exposed to drugs in vitro, indicating that resistance to anticancer drugs can be developed through mechanisms that are exclusively operational in vivo. Liu et al. (1999) reported that inhibition of apoptosis through Bcl-xl overexpression promoted resistance to 5-fluorouracil in tumorigenic breast cancer cell lines in vivo, but not in vitro. The same observation was reported for Bcl-2, (Lock and Stribinskiene, 1996; Schmitt et al., 2000) . Thus, we hypothesized that PTN could influence drug sensitivity exclusively by in vivo operational mechanisms. Angiogenesis is a specific in vivo mechanism that plays an essential role during tumor development. PTN displays a crucial, though debated role in angiogenesis. On the one hand, PTN acts as a mediator of angiogenesis, being capable of inducing proliferation of endothelial cells (Fang et al., 1992; Papadimitriou et al., 2001) . PTN cDNA transfection in breast carcinoma cells enhanced in vivo angiogenic activity although there was no effect on in vitro growth (Choudhuri et al., 1997) . Moreover, tumor angiogenesis was decreased in parallel with reduced PTN levels in nude mice, whereas PTN was not a rate-limiting growth factor for 1205LU melanoma cells in vitro (Czubayko et al., 1996) . On the other hand, PTN was reported to display an inhibitory effect on angiogenesis processes. Heroult et al. (2004) demonstrated by in vitro and in vivo assays that PTN may negatively regulate angiogenesis by inhibiting VEGF biological activity. This angiostatic effect of PTN is attributed to the complex formation between PTN and VEGF. PTN interacts directly with VEGF and can inhibit VEGF binding to its high affinity receptor (Heroult et al., 2004) . It was suggested that different regions of PTN may either induce or inhibit angiogenesis. These controversial results could be explained by the existence of various forms of PTN obtained after proteolytic degradation of the whole molecule and exhibiting distinct biological activities (Polykratis et al., 2004) .
IGR-NB8 IGR-NB8R IGR-NB8 r
Morphologically, vasculature was significantly more abundant in our resistant NB xenograft tumors as compared to sensitive and reverted tumors. Angiogenesis processes may be a determinant factor in the mechanism of resistance of our model. By inhibiting activity of VEGF, a key player in angiogenesis regulation, PTN could participate in this process causing a decrease in vessel density, and thereby enhancing sensitivity to CPT-11 in NB xenografts. Furthermore, it was demonstrated that, to counteract angiogenesis, PTN interacts with VEGF through its central thrombospondin-type I repeat domains. Thus, a full-length or hardly degraded protein and the presence of VEGF are required for the angiostatic potential of PTN (Heroult  et al., 2004, Polykratis et al., 2004) . Strengthening our hypothesis, VEGF expression investigated by ELISA was strong in our NB model as compared to other NB xenografts (data not shown). In addition, analysis of PTN expression in resistant, sensitive and reverted xenografts by Western blot failed to show small truncated PTN products (data not shown). Although other angiogenic and angiostatic molecules could play a role in our resistant NB model, PTN was currently the only very strong candidate gene identified.
The association between intratumor MVD and tumor aggressiveness is now well established; however, the role of intratumor angiogenesis as a yardstick of response to cytotoxic treatment has not been extensively studied. It has been hypothesized that angiogenesis should make a tumor more accessible to drugs and thus more responsive. In reality, the reverse appears to be true. Antiangiogenic therapy before paclitaxel, carboplatin, cyclophosphamide or cisplatin resulted in higher intratumor concentrations of these drugs, thus potentiating antitumor activity (Teicher et al., 1995; Herbst et al., 1998) . Additionally, anti-VEGF therapy did not impair, but even improved intratumor accumulation of CPT-11 in the xenograft tumor model (Wildiers et al., 2003) . Accumulating data indicate that antiangiogenic therapy can potentiate the effects of chemotherapy. The new concept of 'normalizing tumor vasculature' can explain these results. Indeed, tumor vessels are structurally and functionally abnormal, largely composed of immature, hyperpermeable and poorly organized vessels that obstruct the delivery and the effectiveness of cytotoxic therapies. Antiangiogenic therapy targets inadequate and immature vessels, leading to a more normalized tumor vasculature (Jain, 2005) .
In this study, we report for the first time that high PTN expression is associated with poor vasculature. These results strongly support the angiostatic role of PTN through inhibition of VEGF activity (Heroult et al., 2004) and stand in agreement with high PTN expression in favorable NB (Nakagawara et al., 1995) . High PTN expression was closely associated with in vivo sensitivity to CPT-11 in NB, suggesting that PTN could play an important role in NB biology. Mechanistically, we propose that PTN acts as angiostatic factor in NB, inhibiting VEGF-induced angiogenesis and thereby influencing sensitivity to CPT-11 exclusively through an in vivo mechanism. These results emphasize the importance of microenvironmental factors as determinant of drugs resistance acquisition.
Materials and methods
NB xenograft model IGR-NB8 xenograft derived from a newly diagnosed stage 3 abdominal NB in a 5 year-old boy (Vassal et al., 1996) and displayed biological features of poor-prognosis NB: immature neuroblasts, MYCN amplification, a near-diploid karyotype, and 1p deletion. In vivo, IGR-NB8 proved to be sensitive to CPT-11 and topotecan. IGR-NB8 was rendered resistant to CPT-11 through prolonged exposure to CPT-11 given at a dose of 27 mg/kg/day Â 5 every 21 days (one cycle) for a maximum of four cycles (one passage) (Calvet et al., 2004) .
After tumor regrowth, a new in vivo passage was performed and CPT-11 treatment was repeated. After a series of 68 CPT-11 treatment cycles and 28 passages in vivo, IGR-NB8 showed the characteristics of a CPT-11-resistant tumor: no tumor regression was observed after the third passage, whereas the treatment induced 100% of complete and partial regression at the first passage, tumor growth delay decreased significantly from 115 to 17 days. This resistant xenograft was named IGR-NB8-R and was characterized by the presence of crossresistance to another topoisomerase I inhibitor, topotecan, the absence of quantitative or qualitative topoisomerase I modifications, and no overexpression of three members of the ABC transporter family: multidrug resistance 1 (MDR1), multidrug resistance-associated protein 1 (MRP1), and breast cancer resistance protein (BCRP). The acquired resistance of IGR-NB8-R was not permanent. The tumor xenograft recovered its initial sensitivity after 15 passages without treatment (Calvet et al., 2004) . For the study, tumor samples from IGR-NB8 (sensitive), IGR-NB8-R (resistant) and IGR-NB8-r (reverted) were rapidly harvested, frozen in nitrogen liquid, and stored at À801C.
Cell lines and culture
The human NB cell lines SH-SY5Y, CHP-212, NJB, SK-N-AS were kindly provided by Dr Alexander Valent, Laboratory of Oncologic Genetics, Institut Gustave Roussy, IGR-N91 was kindly provided by Pr Jean Benard, Laboratory of Molecular Interactions and Cancer, Institut Gustave Roussy, the IGR-NB8 cell line was established in our laboratory. All cell lines were maintained in Dulbecco's modified Eagle medium (DMEM) (Invitrogen, Life Technologies) supplemented with 10% heat-inactivated fetal bovine serum (Invitrogen, Life Technologies) in 5% CO 2 at 371C.
Total RNA isolation Total RNA from tumors was isolated using RNA-plus reagent (Bioprobe Systems, Montreuil, France) following the manufacturer's instructions. Total RNA was quantified using UV spectrophotometry, quality and integrity of RNA samples were confirmed by electrophoresis in 1% agarose gel stained with ethidium bromide and by microcapillary electrophoresis on a RNA LabChip (Agilent 2100 Bioanalyzer).
cDNA Probe synthesis and array hybridization Atlas Human cDNA Expression Arrays (Clontech Palo Alto, CA, USA), containing 588 cancer-related cDNA and 21 housekeeping genes or negative controls spotted as duplicates on nylon membranes were used. The complete list of genes is available on the Clontech's web site (http://www.clontech. com). The preparation of 32 P-radiolabeled cDNA from 4 mg of total RNA was performed according to the manufacturer's instructions with [a-32 P]dATP (3000 Ci/mmol; Amersham Biosciences). The labeled cDNA probes were purified and probe incorporation assessed by scintillation counting. cDNA probes were hybridized to the nylon membrane according to the procedure described in the Atlas array user manual. After overnight hybridization and a high-stringency wash, the hybridized membrane was exposed to a phosphorimaging screen for 48 h and scanned using a Molecular Dynamics Storm Phosphorimager.
cDNA array analysis The image files generated by the Molecular Dynamics Storm Phosphorimager were analysed with the AtlasImage software. Atlas arrays deliver a linear correlation between hybridization signals and RNA abundance. After normalizing the signal values of all the genes on the arrays (global normalization), the signal intensity was calculated for each spot on the array, and two arrays were compared with each other. The numerical output was exported to Microsoft Excel for comparisons and identification of differentially regulated genes. Genes were considered to display a significant change in expression when the intensity ratio was X1.75.
PTN mRNA gene expression using real-time RT-PCR Of total RNA, 1 mg from each sample was reverse transcribed in a 20 ml reaction using 50 IU of Moloney murine leukemia virus reverse transcriptase (RT) and 20 IU of RNuclease inhibitor (Applied Biosystems, Foster City, CA, USA), 1 mmol/l of dA/T/G/C (Amersham-Pharmacia Biotech, Uppsala, Sweden), 5 mmol/l of MgCl 2 , 2 ml Buffer II 10 Â , and 2.5 mmol/l of random hexamers (Applied Biosystems). The cDNAs were then diluted 1/45 in nuclease-free H 2 O (Promega Corp.). All RNA samples included in the study as well as negative RT controls were prepared using a common mixture. Real-time quantitative PCR was achieved by using a cDNA equivalent of 25 ng of total RNA. The reaction was performed in 50 ml using TaqMan Universal PCR Master Mix PCR core reagents (Applied Biosystems) according to the manufacturer's instructions. PCR was developed with the ABI PRISM 7000 sequence detection system (Applied Biosystems). Amplification was performed using a 2-min step at 501C and a 10-min denaturation step at 951C, followed by 40 cycles of 15 s of denaturation at 951C, 1 min of primer annealing, and a polymerization step at 601C. To normalize for differences in the amount of total RNA in each RT-PCR, amplification of 18S total rRNA was performed as an endogenous control. The primers and probe from 18S and PTN were purchased from Applied Biosystems assay-on-Demandt. The relative expression in each sample was calculated in relation to a standard calibration curve (the dilution series of genomic DNA).
Protein expression analysis
Cellular pellets were lysed in buffer (0.15 NaCl, 1 mM KH 2 PO 4 , 5mM MgCl 2 , 1mM EDTA pH 6.4) containing protease inhibitor cocktail tablets (complete mini, Roche). NaCl (0.55 M) was added for total cell extraction and proteins were detected by the BCA method (Pierce). Equal amounts of proteins were separated electrophoretically in 16% SDSpolyacrylamide gels and transferred to a nitrocellulose membrane (Hybond P Amersham Life Science). Blots were incubated with a goat polyclonal anti-human PTN antibody (R&D Systems) at 0.2 mg/ml, followed by an anti-goat horseradish-peroxidase-conjugated antibody (Dako), and a chemiluminescence (ECL-plus) enzyme immunoassay (Amersham Pharmacia Biotech).
Cell viability using MTT assay Cells were seeded into 96-well plates at a density of 3.10 4 -10.10 4 cells/well in DMEM medium with 10% FBS and were treated with various concentrations of SN-38 and topotecan for 72 h. Cell viability was determined by a colorimetric assay. Of the tetrazolium salt 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (5 mg/ml) (Sigma Aldrich), 10 ml, were added to each well, incubated at 371C for 4 h and lysed with 100 ml of lysis buffer (NN'dimethyle formamide, 20% SDS) for 2 h at 371C. Multiskan Ex (Thermo electron corporation) was used to measure absorbance at 560 nm. All experiments were performed in sextuplicate and repeated in at least two different experiments. Untreated controls were assigned a value of 100% viability.
siRNA knockdown experiments
The pRS (Brummelkamp et al., 2002) short interfering (si)RNA expression system was used to stably suppress PTN expression. The pRS vector was a kind gift from Dr Reuven Agami (The Netherlands Cancer Institute, Amsterdam, the Netherlands). The pRS plasmid was propagated in Escherichia coli under ampicillin selection. The target sequences used to silence PTN were generated as described by Brummelkamp et al. (2002) . The successful 64-bp linker sequence was: Forward primer, 5 0 -gatccccCTGGAAGTCTGAAGCGAGCtt caagaga-GCTCGCTT CAGACTTCCAGtttttggaaa-3 0 , Reverse primer, 5 0 agcttttccaaaaaCTGGAAGT-CTGAAGCGA GCtctcttgaaGCTCGCTTCAGACTTCCAGggg-3 0 . The pRetro-SUPER vector was digested with BglII/HindIII and ligated with double-strand oligonucleotides to form pRS-PTN. SK-N-AS and IGR-NB8 cells were transfected with Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's instructions and transfected cells were selected by 2 mg/ml puromycin.
Immunohistochemical analyses of microvessels
Frozen IGR-NB8, IGR-NB8-R and IGR-NB8-r tumors were fixed in Finefix (Milestone, Italy), paraffin-embedded, and cut in 4 mm thick sections. Microvessels were detected using an anti-CD34 antibody directed against murine endothelial cells (HyCult biotechnology b.v., The Netherlands). After endogenous peroxidase blocking, sections were incubated with antimouse CD34, diluted 1:20 for 1 h. Staining was revealed by a rabbit anti-rat antibody, 1:200 (Dako, Denmark), Rabbit PowerVision kit (ImmunoVision Technologies, CA, USA) and DAB. Slides were counterstained with Mayer's hematoxilin.
Image acquisition and quantification of blood vessels A single image of the whole histological section of each specimen was recorded, using a Nikon SuperCoolscan 8000 ED slide scanner equipped with a FH-8G1 medical slide holder (Nikon, Champigny sur Marne, France). Acquisition conditions were standardized in order to ensure restitution of the same colors and equal intensities, for all images . The resolution used was 4000 dots per inch with 1 pixel covering an area of 40 mm 2 . Images of the histological sections were processed using PixCyt s image analysis software Kim et al., 2003) . The procedure is fully automatic. All MVD profiles are expressed as the number of vessels per mm 2 of tumor tissue. MSP is the sum of the areas covered by microvessels divided by the total tumor area multiplied by 100, which expresses the percentage of the tumor covered by microvessels. Statistical analysis of MVD and MSP between groups was performed with Mann-Whitney and Kruskal-Wallis tests, using Prism 3 (GraphPad Software, Inc, san Diego, CA, USA).
Abbreviations NB, neuroblastoma; PTN, pleiotrophin; siRNA, small interfering RNA; pRS, pRetroSuper; MDR, multidrug resistance; MRP, multidrug resistance-associated protein; BCRP, breast cancer resistance protein.
